×
About 499,350 results

Investigation into SARS-CoV‑2 Resistance of Compounds in Garlic Essential Oil
https://pubs.acs.org/doi/pdf/10.1021/acsomega.0c00772

Eighteen active substances, including 17 organosulfur compounds found in garlic essential oil (T), were identified by GC−MS analysis. For the first time, using the molecular docking technique, we report the inhibitory effect of the considered compounds on the host receptor angiotensin-converting enzyme 2 (ACE2) protein in the human body that leads to a crucial foundation about coronavirus ...

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c00272

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vacc...

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700135/
Scientific Reports;

Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of Parkinson’s disease patients. Neurovascular dysregulation in putaminal and pallidal regions is thought to be an underlying feature of this complication of treatment. We used microPET to study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after ...

Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses
https://www.sciencedirect.com/science/article/pii/S1286457920300538

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
https://www.nature.com/articles/s41586-020-2598-9_reference.pdf
Nature

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic1,2 . Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms determining such variable outcomes remain unresolved. Here, we investigated SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cel...

Introductions and early spread of SARS-CoV-2 in the New York City area
https://science.sciencemag.org/content/369/6501/297
Science

New York City (NYC) has emerged as one of the epicenters of the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. To identify the early transmission events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus that causes coronavirus disease 2019 (COVID-19) in patients seeking care at the Mount Sinai Health System. Phylogeneti...

Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 16th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.

Efficacy of Cabozantinib in Previously Treated RCC Is Consistent Irrespective of Prior Therapy
https://www.targetedonc.com/view/efficacy-of-cabozantinib-in-previously-treated-rcc-is-consistent-irrespective-of-prior-therapy

May 29th, 2020 - A pooled analysis of clinical trial data revealed that systemic therapy with cabozantinib (Cabometyx) in advanced renal cell carcinoma (RCC) induced reliable responses for patients regardless of whether or not they had received prior immunotherapy. Patients from both the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C2001 (NCT03339219) trials comprised the efficacy population whose resu...

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated the agent's manageable safety profile, according to an interim analysis of the phase 2 ZUMA-5 study (NCT03105336) presented as part of the 2020 American...

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Imaging in Parkinson’s disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280219/
Clinical Medicine;

The clinical presentation of Parkinson’s disease (PD) is heterogeneous and overlaps with other conditions, including the parkinsonian variant of multiple system atrophy (MSA-P), progressive supranuclear palsy (PSP) and essential tremor. Imaging of the brain in patients with parkinsonism has the ability to increase the accuracy of differential diagnosis. Magnetic resonance imaging (MRI), single ...

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 30th, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy regardless of prior therapy, according to data from a pooled analysis of patients treated on the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C20...

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumab-doubles-24month-pfs2-in-pdl1-hnscc

May 29th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.

Tivozanib Showcases Superiority in Relapsed/Refractory RCC
https://www.onclive.com/conference-coverage/asco-2020/final-data-analysis-supports-tivozanib-as-superior-treatment-for-patients-with-rcc

May 28th, 2020 - Tivozanib (Fotivda) demonstrated a significant improvement in progression-free survival (PFS) compared with sorafenib (Nexavar), with similar overall survival (OS), in patients with highly relapsed.refractory metastatic renal cell carcinoma (RCC), according to results of the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program.

Analysis of factors associated with brittle response in patients with Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.51028

The brittle response (BR) in patients with Parkinson’s disease (PD) refers to a special type of levodopa‐induced dyskinesia (LID). This study aimed to describe the clinical characteristics of BR patients and to analyze the associated risk factors.

Brain-Region Specific Metabolic Abnormalities in Parkinson's Disease and Levodopa-Induced Dyskinesia
https://www.frontiersin.org/articles/10.3389/fnagi.2020.00075/full
Frontiers in Aging Neuroscience;

Several lines of evidence point to alteration in brain metabolic homeostasis in Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID), yet the metabolic mechanism in different brain regions underlying PD and LID remains largely unknown. The present study aimed to uncover the metabolic pathways across anatomical regions in the brain of PD and LID. Using an NMR-based metabolomic approach...

Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31142-9.pdf
The Lancet;

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 and is spread personto-person through close contact. We aimed to investigate the effects of physical distance, face masks, and eye protection on virus transmission in health-care and non-health-care (eg, community) settings.

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
https://www.nature.com/articles/s41531-018-0069-x
NPJ Parkinson's Disease;

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, de...

The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis
https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1.full.pdf

Respiratory failure is a key feature of severe Covid-19 and a critical driver of mortality, but for reasons poorly defined affects less than 10% of SARS-CoV-2 infected patients. Methods. We included 1,980 patients with Covid-19 respiratory failure at seven centers in the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe (Milan, Monza, Madrid, San Sebastian and Barcelona) for a...

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
https://ascopost.com/news/june-2020/carfilzomib-vs-bortezomib-in-addition-to-lenalidomidedexamethasone-in-newly-diagnosed-multiple-myeloma/

May 31st, 2020 - The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity in the randomized phase III ENDURANCE trial were presented in the P...